MIAMI--(BUSINESS WIRE)--Feb. 21, 2006--DOR BioPharma, Inc. (AMEX: DOR) (“DOR”, or the “Company”) announced today that survival results for orBec(R) (or oral beclomethasone dipropionate) from two randomized, double-blinded, placebo-controlled clinical trials for the treatment of patients with gastrointestinal Graft-versus-Host disease (iGVHD), were presented by George B. McDonald, MD, inventor of orBec(R), at the annual Tandem Bone Marrow Transplant Meeting of the American Society for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry in Honolulu on February 18, 2006 in a presentation entitled “Oral beclomethasone dipropionate for gastrointestinal GVHD: a corticosteroid-sparing treatment with improved survival at day-200.” An abstract of this presentation has been published (Biology of Blood and Marrow Transplantation 2006; 12 (Supplement 1): 1-2). The abstract was chosen to receive a Best Abstracts Award at the conference.
